ZA200404113B - Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist - Google Patents

Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist

Info

Publication number
ZA200404113B
ZA200404113B ZA200404113A ZA200404113A ZA200404113B ZA 200404113 B ZA200404113 B ZA 200404113B ZA 200404113 A ZA200404113 A ZA 200404113A ZA 200404113 A ZA200404113 A ZA 200404113A ZA 200404113 B ZA200404113 B ZA 200404113B
Authority
ZA
South Africa
Prior art keywords
toll
tumor
methods
combination
treating cancer
Prior art date
Application number
ZA200404113A
Other languages
English (en)
Inventor
Alain P Vicari
Caux Christophe
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200404113B publication Critical patent/ZA200404113B/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200404113A 2001-11-27 2004-05-26 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist ZA200404113B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33343401P 2001-11-27 2001-11-27

Publications (1)

Publication Number Publication Date
ZA200404113B true ZA200404113B (en) 2006-03-29

Family

ID=23302758

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200404113A ZA200404113B (en) 2001-11-27 2004-05-26 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist

Country Status (14)

Country Link
US (2) US20030138413A1 (zh)
EP (1) EP1450858A2 (zh)
JP (3) JP2006502080A (zh)
CN (1) CN1617742B (zh)
AU (1) AU2002359516B2 (zh)
BR (1) BR0214457A (zh)
CA (1) CA2468320A1 (zh)
HU (1) HUP0500999A2 (zh)
MX (1) MXPA04004998A (zh)
NO (1) NO20042697L (zh)
NZ (1) NZ565420A (zh)
TW (1) TW200303759A (zh)
WO (1) WO2003045431A2 (zh)
ZA (1) ZA200404113B (zh)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
PT1077722E (pt) * 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US20040175355A1 (en) * 2001-04-18 2004-09-09 The Regents Of The University Of California Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
ATE447967T1 (de) 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
JP2006512391A (ja) * 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
EP1599572A4 (en) * 2003-02-14 2007-06-13 Univ Southern California COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
CA2544240A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
CA2555390C (en) * 2004-02-19 2014-08-05 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
WO2006112869A2 (en) * 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
RU2401661C9 (ru) * 2004-07-20 2011-01-27 Шеринг Корпорейшн Индукция апоптоза в опухолевых клетках, экспрессирующих toll-подобный рецептор
US20080274140A1 (en) * 2004-11-19 2008-11-06 David B Weiner Vaccines and Methods for Using the Same
US20080166369A1 (en) * 2004-12-28 2008-07-10 Immuno Frontier, Inc. Cancer Vaccine Preparation
EP1712241A1 (en) * 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
US20100143899A1 (en) * 2005-05-17 2010-06-10 University Of Vermont And State Agricultural College Methods and products for diagnosing cancer
CN101501055B (zh) * 2005-06-23 2016-05-11 贝勒医学院 负性免疫调节因子的调节和免疫疗法应用
MX2008000596A (es) * 2005-07-11 2008-03-19 Cbio Ltd Inmunomodulacion inducida por la chaperonina 10.
CN101394865B (zh) * 2005-12-01 2013-02-13 都柏林伊丽莎白女皇神学院院长、研究员及专家协会 癌症和传染病治疗的组合物及方法
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
DK2032592T3 (da) 2006-06-12 2013-09-02 Cytos Biotechnology Ag Fremgangsmåder til pakning af oligonukleotider til virus-lignende partikler af rna-bakteriofager
DE102006035618A1 (de) * 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
CA2671883A1 (en) * 2006-12-12 2008-06-19 Idera Pharmaceuticals, Inc. Synthetic agonists of tlr9
US8445442B2 (en) * 2007-04-26 2013-05-21 University Of Vermont And State Agricultural College CCL18 and CCL3 methods and compositions for detecting and treating cancer
EP2222344A4 (en) * 2007-11-30 2012-11-07 Baylor College Medicine DENDRITIC CELL VACCINE COMPOSITIONS AND USES THEREOF
CN102300990A (zh) * 2009-01-30 2011-12-28 艾德拉药物股份有限公司 Tlr9的合成激动剂
BR112012013736A2 (pt) 2009-12-07 2018-08-14 Univ Leland Stanford Junior processo para intesificação de terapia com anticorpos antitumor
WO2011097384A2 (en) * 2010-02-04 2011-08-11 Board Of Regents, The University Of Texas System Tumor targeted delivery of immunomodulators by nanoplymers
WO2011097573A2 (en) 2010-02-05 2011-08-11 Mount Sinai School Of Medicine Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
US9890202B2 (en) 2010-07-19 2018-02-13 Yeda Research And Development Co. Ltd. Peptides based on the transmembrane domain of a toll-like receptor (TLR) for treatment of TLR-mediated diseases
US20120039916A1 (en) * 2010-08-13 2012-02-16 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
WO2013185052A1 (en) * 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
EP3033417B1 (en) * 2012-06-27 2019-12-25 Kenichiro Hasumi Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10
EP2894173B1 (en) 2012-09-05 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Hyaluronic acid derivative having amino acid and steryl group introduced thereinto
CN103768604B (zh) * 2012-10-24 2016-03-30 北京圣沃德生物科技有限公司 治疗性肿瘤疫苗
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
CN103013915B (zh) * 2013-01-09 2014-05-28 高岱清 一种高活性负载抗原的树突状细胞的制备方法
EP2991655B1 (en) 2013-04-29 2024-04-10 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
EP3653637A1 (en) 2013-05-18 2020-05-20 Aduro BioTech, Inc. Compositions and methods for activating "stimulator of interferon genes"-dependent signalling
EP3024936B1 (en) 2013-07-25 2019-09-04 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
CA2953216C (en) 2014-06-04 2020-12-22 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3603661A3 (en) 2015-04-22 2020-04-01 CureVac AG Rna containing composition for treatment of tumor diseases
US20180127717A1 (en) * 2015-05-07 2018-05-10 Baylor College Of Medicine Dendritic cell immunotherapy
AU2016256911B2 (en) 2015-05-07 2022-03-31 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
US20180161427A1 (en) * 2015-05-29 2018-06-14 Merck Sharp & Dohme Corp. Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer
JP6792294B2 (ja) * 2015-05-29 2020-11-25 ダイナバックス テクノロジーズ コーポレイション 肺のがんを処置するためのポリヌクレオチドのＴｏｌｌ様受容体９アゴニストの肺内投与
CA2994965A1 (en) * 2015-08-06 2017-02-09 Memorial Sloan-Kettering Cancer Center Methods and compositions for tumor therapy
TW201716084A (zh) * 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
US11447557B2 (en) 2015-12-02 2022-09-20 Agenus Inc. Antibodies and methods of use thereof
WO2017192470A1 (en) * 2016-05-03 2017-11-09 Merck Sharp & Dohme Corp. Combination therapy of anti-il-10 antibody and compositions comprising lipid nanoparticles and tlr9 agonist cpg oligonucleotides
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018060513A1 (en) 2016-09-30 2018-04-05 Galderma Research & Development Methods and compositions for treating precancerous lesions or cancer comprising tlr/tlr or tlr/clr agonists
WO2018060514A1 (en) 2016-09-30 2018-04-05 Galderma Research & Development Methods and compositions combining at least one pattern recognition receptor (prr) agonist with an anti-il10 receptor antibody
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
CA3053939A1 (en) * 2017-02-17 2018-08-23 Aivita Biomedical, Inc. Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells
JP7348074B2 (ja) * 2017-06-04 2023-09-20 ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズ がん治療に対する個別化応答の予測方法およびそのキット
JP7420751B2 (ja) * 2018-06-19 2024-01-23 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｉ型インターフェロン及びｃｄ４０－配位子を用いる腫瘍溶解性ウイルス又は抗原提示細胞媒介性癌治療
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
EP4175673A1 (en) 2020-07-01 2023-05-10 ARS Pharmaceuticals Inc. Anti-asgr1 antibody conjugates and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006830A1 (en) * 1986-05-09 1987-11-19 Sloan-Kettering Institute For Cancer Research Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment
EP0673252A4 (en) * 1992-12-14 1998-07-15 Start Technology Partnership ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES TO THE DOPAMIN RECEPTOR RNA MESSENGER FOR DIAGNOSING AND TREATING NEUROLOGICAL CONDITIONS.
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DK0772619T4 (da) * 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
ATE292980T1 (de) * 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
CA2323929C (en) * 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
TR200103018T2 (tr) * 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
AU2001239873A1 (en) * 2000-02-24 2001-09-03 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant treatment by in vivo activation of dendritic cells
CN1441677A (zh) * 2000-03-31 2003-09-10 Idec药物公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用

Also Published As

Publication number Publication date
US20030138413A1 (en) 2003-07-24
HUP0500999A2 (en) 2007-11-28
AU2002359516A1 (en) 2003-06-10
EP1450858A2 (en) 2004-09-01
JP2006502080A (ja) 2006-01-19
JP2010053140A (ja) 2010-03-11
CN1617742A (zh) 2005-05-18
US20090087440A1 (en) 2009-04-02
CN1617742B (zh) 2010-10-27
CA2468320A1 (en) 2003-06-05
TW200303759A (en) 2003-09-16
JP2006131638A (ja) 2006-05-25
WO2003045431A2 (en) 2003-06-05
BR0214457A (pt) 2006-11-21
WO2003045431A3 (en) 2004-01-22
NZ565420A (en) 2009-09-25
AU2002359516B2 (en) 2006-02-02
NO20042697L (no) 2004-06-25
MXPA04004998A (es) 2005-04-08

Similar Documents

Publication Publication Date Title
HUP0500999A2 (en) Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
IL147695A0 (en) Method of treating certain cancers using an estrogen agonist/antagonist
HK1254085A1 (zh) 用於癌症預後的表達譜演算法和測試
GB2399636B (en) Methods and systems for determining formation properties and in-situ stresses
IL145453A0 (en) Methods for treating osteoarthritis using an estrogen agonist/antagonist
EP1653960A4 (en) MELANIN CONCENTRATION HORMONE RECEPTOR ANTAGONIST
HK1103654A1 (zh) 個使用種血管內皮細胞生長因子 對抗劑的治癌方法
EP1460982A4 (en) METHODS FOR INITIATING IN SITU FORMATION OF HYDROGELS
AU2003214873A1 (en) Methods of treating conditions associated with an edg receptor
AU2002353081A1 (en) Pulsatile release histamine h2 antagonist dosage forms
EP1487471A4 (en) METHOD FOR TREATING AUTOIMMUNE DISEASES AND ASSOCIATED REAGENTS
PL379420A1 (pl) Pochodne blokerów receptora angiotensyny II
AU2001273413A1 (en) Method for treating cancer using an interleukin- 4 antagonist
AU2003217783A8 (en) Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
EP1453503A4 (en) EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
IL152082A0 (en) Estrogen agonist/antagonist metabolites
AU2002308522A8 (en) Methods for inhibiting tumor cell proliferation
EP1436423A4 (en) GENETIC ANALYSIS TO STRATIFY CANCER RISK
EP1569516A4 (en) METHOD OF INHIBITING CANCER AND TARGET EDUCATION
AU2002359524A8 (en) P2x7 receptor antagonists
EP1534317A4 (en) N-TERMINAL TRONQUEE GALECTIN-3 AND ANTIBODIES FOR THE TREATMENT OF CANCER
EP1575512A4 (en) METHOD AND COMPOSITIONS FOR THE EPITHELIAL CELL DIFFERENTIATION IN THE PROSTATE
AU2001278068A1 (en) Methods and compositions for predicting prostate cancer
GB0101223D0 (en) Histamine receptor antagonists
AU2003247052A1 (en) Mcp-1 receptor antagonists and method of use thereof